Article

Ability of nucleoside-modified mRNA to encode HIV-1 envelope trimer nanoparticles

2021-08-09

Abstract excerpt

<h4>SUMMARY</h4> The success of nucleoside-modified mRNAs in lipid nanoparticles (mRNA-LNP) as COVID-19 vaccines heralded a new era of vaccine development. For HIV-1, multivalent envelope (Env) trimer protein nanoparticles are superior immunogens compared to trimers alone for priming of broadly neutralizing antibody (bnAb) B cell lineages. The successful expression of complex multivalent nanoparticle immunogens w...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 0f6b56c5-87d5-55cf-b040-f70058600e97
DOI: 10.1101/2021.08.09.455714

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Ability of nucleoside-modified mRNA to encode HIV-1 envelope trimer nanoparticlesDOI 10.1101/2021.08.09.455714Read

mRNA-encoded HIV-1 Env trimer ferritin nanoparticles induce monoclonal antibodies that neutralize heterologous HIV-1 isolates in miceSemantic proximity Read

Comparison of the immunogenicity of mRNA-encoded and protein HIV-1 Env–ferritin nanoparticle designsSemantic proximity Read

Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primatesSemantic proximity Read

Vaccination with mRNA-encoded nanoparticles drives early maturation of HIV bnAb precursors in humansSemantic proximity Read

mRNA Vaccine Platforms and Lipid Nanoparticle Delivery Systems: Molecular Advances, Clinical Breakthroughs, and Regulatory Perspectives (2020–2025)Semantic proximity Read

Antigen Delivery Platforms for Next-Generation Coronavirus Vaccines: The Superiority of Nucleoside-Modified mRNA Encapsulated in Lipid Nanoparticles Vaccine PlatformSemantic proximity Read

Engineering of the current nucleoside-modified mRNA-LNP vaccines against SARS-CoV-2Semantic proximity Read

Nanoparticle Vaccines for Inducing HIV-1 Neutralizing AntibodiesSemantic proximity Read

Advancing mRNA vaccines for infectious diseases: key components, innovations, and clinical progressSemantic proximity Read

mRNA Vaccines Five Years After COVID-19: Lessons in Platform Design, Real-World Effectiveness, and EquitySemantic proximity Read

mRNA Vaccines: Design Principles, Mechanisms, and Manufacturing—Insights From COVID‐19 as a Model for Combating Infectious DiseasesSemantic proximity Read

Polymer-lipid hybrid nanoparticle enhances mRNA delivery and T cell-mediated immunitySemantic proximity Read